Newsroom|Lundbeck US

Lundbeck US Charitable Fund Awards More than $4 Million to Organizations Increasing Access to Mental Health Care for US Veterans and the Military Community

Lundbeck US Charitable Fund Awards More than $4 Million to Organizations Increasing Access to Mental Health Care for US Veterans and the Military Community

0

ABOUT THE NEWSROOM

Here you will find media contacts, plus the latest news, stories and insights from Lundbeck US. Lundbeck is a global pharmaceutical company
solely focused on the brain, and our 900+ U.S. employees are committed to improving the lives of people affected by psychiatric and neurological disorders.

Otsuka and Lundbeck announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD)

Otsuka and Lundbeck announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD)

0

Lundbeck to Present a Breadth of Migraine and Cluster Headache Data at the 66th Annual Scientific Meeting of the American Headache Society

Lundbeck to Present a Breadth of Migraine and Cluster Headache Data at the 66th Annual Scientific Meeting of the American Headache Society

0

Otsuka and Lundbeck Present Results from Three Clinical Trials of Brexpiprazole in Combination with Sertraline for the Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults

Otsuka and Lundbeck Present Results from Three Clinical Trials of Brexpiprazole in Combination with Sertraline for the Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults

0

Lundbeck to Present Data on Migraine Impact Reduction and Sustained Response with VYEPTI® (eptinezumab-jjmr) at 76th Annual Meeting of the American Academy of Neurology

Lundbeck to Present Data on Migraine Impact Reduction and Sustained Response with VYEPTI® (eptinezumab-jjmr) at 76th Annual Meeting of the American Academy of Neurology

0

Connecting with the Unsung Heroes of Alzheimer’s Disease

Connecting with the Unsung Heroes of Alzheimer’s Disease

Alzheimer's Disease

0

JAMA Neurology Publishes Complete Results of Positive Phase 3 Study of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease

JAMA Neurology Publishes Complete Results of Positive Phase 3 Study of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease

0